$127.35
-4.20-3.19%
Ultimo aggiornamento: Nov 18, 11:05 AM
Novartis segnala gli utili su base trimestrale. Questi report sugli utili trimestrali offrono agli investitori uno sguardo ai risultati finanziari di un'azienda per un periodo di 3 mesi. I report sugli utili includono quasi sempre i risultati EPS e i ricavi.
Analizza lo storico degli utili di Novartis utilizzando ordinamenti e filtri avanzati.
Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
NVS | Novartis | $1.98 | $1.93 | — | — | $13.15B | $13.67B | — | — | 01/30/2026 | |
NVS | Novartis | $2.06 | $2.29 | $2.25 | -1.75% | $12.82B | $13.87B | $13.91B | 0.30% | 10/28/2025 | |
NVS | Novartis | $1.97 | $2.38 | $2.47 | 3.78% | $12.51B | $14.06B | $14.05B | -0.08% | 07/17/2025 | |
NVS | Novartis | $1.80 | $2.08 | $2.28 | 9.62% | $11.83B | $12.99B | $13.23B | 1.87% | 04/29/2025 | |
NVS | Novartis | $1.53 | $1.79 | $1.98 | 10.61% | $11.42B | $12.77B | $13.15B | 3.00% | 01/31/2025 | |
NVS | Novartis | $1.74 | $1.96 | $2.06 | 5.10% | $11.78B | $12.70B | $12.82B | 0.97% | 10/29/2024 | |
NVS | Novartis | $1.83 | $1.86 | $1.97 | 5.91% | $11.44B | $12.28B | $12.51B | 1.89% | 07/18/2024 | |
NVS | Novartis | $1.71 | $1.69 | $1.80 | 6.51% | $12.95B | $11.48B | $11.83B | 3.04% | 04/23/2024 | |
NVS | Novartis | $1.52 | $1.68 | $1.53 | -8.93% | $12.69B | $11.56B | $11.42B | -1.19% | 01/31/2024 | |
NVS | Novartis | $1.58 | $1.70 | $1.74 | 2.35% | $12.54B | $11.40B | $11.78B | 3.35% | 10/24/2023 | |
NVS | Novartis | $1.56 | $1.66 | $1.83 | 10.24% | $12.78B | $13.17B | $13.62B | 3.42% | 07/18/2023 | |
NVS | Novartis | $1.46 | $1.55 | $1.71 | 10.32% | $12.53B | $12.64B | $12.95B | 2.48% | 04/25/2023 | |
NVS | Novartis | $1.40 | $1.44 | $1.52 | 5.56% | $13.23B | $13.13B | $12.69B | -3.35% | 02/01/2023 | |
NVS | Novartis | $1.71 | $1.57 | $1.58 | 0.64% | $13.03B | $12.99B | $12.54B | -3.44% | 10/25/2022 | |
NVS | Novartis | $1.66 | $1.52 | $1.56 | 2.63% | $12.96B | $13.01B | $12.78B | -1.76% | 07/19/2022 | |
NVS | Novartis | $1.52 | $1.44 | $1.46 | 1.39% | $12.41B | $12.73B | $12.53B | -1.56% | 04/26/2022 | |
NVS | Novartis | $1.34 | $1.42 | $1.40 | -1.41% | $12.77B | $13.30B | $13.23B | -0.53% | 02/02/2022 | |
NVS | Novartis | $1.52 | $1.65 | $1.71 | 3.64% | $12.26B | $13.03B | $13.03B | 0.00% | 10/26/2021 | |
NVS | Novartis | $1.36 | $1.52 | $1.66 | 9.21% | $11.35B | $12.51B | $12.96B | 3.57% | 07/21/2021 | |
NVS | Novartis | $1.56 | $1.59 | $1.52 | -4.40% | $12.28B | $12.51B | $12.41B | -0.79% | 04/27/2021 | |
NVS | Novartis | $1.32 | $1.36 | $1.34 | -1.47% | $12.40B | $12.87B | $12.77B | -0.78% | 01/26/2021 |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q3 | 2025-10-28 | $2.25 | $2.29 | -1.75 % |
| Q2 | 2025-07-17 | $2.47 | $2.38 | 3.78 % |
| Q1 | 2025-04-29 | $2.28 | $2.08 | 9.62 % |
| Q4 | 2025-01-31 | $1.98 | $1.79 | 10.6 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q3 | 2025-10-28 | $13.91B | $13.87B | 0.30 % |
| Q2 | 2025-07-17 | $14.05B | $14.06B | -0.08 % |
| Q1 | 2025-04-29 | $13.23B | $12.99B | 1.87 % |
| Q4 | 2025-01-31 | $13.15B | $12.77B | 3.00 % |
Si prevede che Novartis (NVS) fornisca risultati il gennaio 30, 2026. Gli ultimi risultati sono stati pubblicati il ottobre 28, 2025 per il Q3.
L'EPS effettivo era $2.25, che mancato la stima di $2.29.
Le entrate effettive sono state $13.9B, che superato la stima di $13.9B.
Sfoglia stime sugli utili, EPS e ricavi su tutte le azioni.